$Immunocore (IMCR.US)$ On September 22, Immunocore Announced...
$Immunocore(IMCR.US$ On September 22, Immunocore Announced that data from a Phase 3 clinical trial of tebentafusp, a novel T cell receptor bi-specific immunotherapy for the first-line treatment of metastatic uveal melanoma, were published in the New England Journal of Medicine. The results showed that tebentafusp significantly prolonged the overall survival of patients compared with the active control group. Tebentafusp is the first systemic TCR therapy to extend life in these patients and has the potential to be a new treatment option for this poorly prognostic disease, the paper notes.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Joare : any thought on the trends of this stock?
yefternOP Joare: Keep looking